Pre-IPO Anduril Stock Climbs 50% in 5 Months

Anduril's reported private valuation has risen to roughly $90 billion, up 48% in five months, implying about 21 times projected 2026 sales of $4.3 billion. Reuters estimates the company will lose $1 billion this year, and the article says it has committed $3.7 billion to a capital-intensive shipyard; the author views the valuation as excessive ahead of a possible IPO.

Analysis

The key issue is not whether a 21x sales multiple is high versus legacy defense—it is whether projected growth converts into durable, cash-generative production. A tender-offer mark is weak price discovery: limited liquidity, share-class terms, and employee liquidity needs can all support a headline valuation without establishing what public investors would pay. The announced shipyard commitment adds a second-order constraint: scaling hardware while funding capacity can absorb cash and management attention before unit economics are proven. Verify whether the reported revenue trajectory is contracted, delivered, and recognized, and whether the shipyard spend is incremental to the cited loss outlook.

For listed defense primes, Anduril’s growth is a long-run competitive risk if it wins repeat procurement and displaces incumbent programs; it is not yet evidence of near-term earnings impairment. Incumbents may also benefit if autonomous systems expand defense budgets or if they partner with suppliers rather than lose programs. The contrarian case is that legacy-defense sales multiples understate the value of a faster-growing technology platform—but that premium only holds if production, contract conversion, and margins scale.

Near term, private-market repricing may sustain IPO excitement, but there is no direct public-equity exposure to Anduril. Over 1–3 months, tender terms, contract awards, and cash-burn disclosures matter more than the valuation headline. Over 6–18 months, delivery execution and funding needs determine whether growth reduces or compounds financing risk. A failed production ramp, worsening cash burn, or delayed awards would falsify the bullish growth-premium case.

Key Decisions for Investors

• Do not trade the tender valuation as a public-market mark. If an IPO is announced, wait for offering terms and scrutinize dilution, share classes, use of proceeds, and the valuation against delivered revenue and cash flow—not headline bookings.
• Keep Anduril on an IPO watchlist rather than initiating a proxy position. Reassess only when the company discloses contract conversion, gross-margin trajectory, cash burn, and how the shipyard commitment is funded.
• For listed defense exposure, avoid shorting incumbents solely on this valuation news. Track repeat awards and program displacement; consider reducing incumbent exposure only if procurement data shows sustained share loss, while recognizing that broader autonomy spending could benefit both challengers and primes.
• Falsification checks: a material reduction in the reported revenue outlook, rising cash burn beyond the cited loss trajectory, shipyard delays or cost escalation, or evidence that awards are not converting into deliveries would strengthen the caution; repeat production awards with improving cash economics would weaken it.